Ataraxis AI is an innovative precision medicine company that operates at the cutting edge of multi-modal artificial intelligence and oncology. The company is dedicated to transforming cancer treatment by developing AI-native tools that assist physicians in selecting optimal therapies for their patients. With a mission to impact at least 50% of new cancer cases by 2030, Ataraxis has made significant strides, including a validation study that improved the accuracy of breast cancer tests by 30%. The company boasts a team of leading AI researchers, medical doctors, and industry veterans, supported by prominent advisors in the field. Backed by $24 million in funding from top venture capital firms, Ataraxis fosters a collaborative and empowering work environment, encouraging team members to contribute actively to the future of healthcare.